Fengyan Jin
Clinical trials sponsored by Fengyan Jin, explained in plain language.
-
New combo therapy aims to control multiple myeloma after first return
Disease control Recruiting nowThis study looks at a drug combination (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has come back for the first time. The goal is to see how well it controls the cancer and delays further progression. About 50 adults will take part, and the stu…
Sponsor: FengYan Jin • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Tailored therapy could boost outcomes in elderly myeloma patients
Disease control Recruiting nowThis study tests a personalized treatment plan for people aged 65 and older with newly diagnosed multiple myeloma. The treatment is adjusted based on each patient's frailty level to improve effectiveness and reduce side effects. About 131 participants will receive a combination o…
Sponsor: FengYan Jin • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC